Metabolic Exercise Test Data Combined with Cardiac and Kidney Indexes (MECKI) Score Evolution: Identification of Cardiovascular Risk in Patients with Heart Failure
Launched by CENTRO CARDIOLOGICO MONZINO · Mar 18, 2025
Trial Information
Current as of April 23, 2025
Recruiting
Keywords
ClinConnect Summary
The MECKI trial is studying a new way to assess the risk of heart problems in patients with heart failure. Heart failure affects not just the heart but also other organs, making it important to consider various factors for a complete understanding of a patient's health. This trial aims to refine a scoring system called the MECKI score, which combines information from exercise tests and other health data to help predict the risk levels more accurately. By updating this score with new patient data and treatment approaches, the goal is to improve its effectiveness for different groups of patients.
To participate in the trial, individuals must be over 18 years old and have a history of heart failure with specific heart function measurements. Key factors include stable health conditions and having previously undergone an exercise test. Participants can expect to provide information about their health and potentially help improve how heart failure is managed in the future. Overall, this trial could lead to better risk assessments, helping doctors provide more personalized care for patients with heart failure.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • age \>18 past or present heart failure (NYHA functional class I-III, stage C of the ACC/AHA classification)
- • documentation of left ventricular systolic dysfunction (LVEF \<40%)
- • stable clinical conditions
- • previous or concomitant cardiopulmonary exercise test
- Exclusion Criteria:
- • scheduled cardiovascular treatment
- • clinical unstable condition
- • History of pulmonary embolism, significant valvular disease, pericardial disease, severe COPD, exercise-induced angina, exercise-induced ECG changes, severe brady- or tachyarrhythmias, or the presence of comorbidities that interfere with exercise performance.
About Centro Cardiologico Monzino
Centro Cardiologico Monzino (CCM) is a leading cardiovascular research and treatment facility based in Milan, Italy, renowned for its commitment to advancing cardiac care through innovative clinical trials and cutting-edge research. Affiliated with the Italian Ministry of Health, CCM specializes in a comprehensive range of cardiovascular services, including diagnostics, interventional cardiology, and rehabilitation. The institution is dedicated to fostering collaboration among healthcare professionals, researchers, and patients to enhance the understanding of cardiovascular diseases and improve therapeutic outcomes. With a focus on translating scientific discoveries into clinical practice, CCM plays a pivotal role in shaping the future of cardiovascular medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Milano, , Italy
Brescia, , Italy
Piacenza, , Italy
Roma, , Italy
Napoli, , Italy
Napoli, , Italy
Bergamo, , Italy
Brescia, , Italy
Roma, , Italy
Ancona, , Italy
San Donato Milanese, Milan, Italy
Trieste, , Italy
Milano, , Italy
Rome, , Italy
Foggia, , Italy
Bari, , Italy
Milano, , Italy
Milano, , Italy
Milano, , Italy
Milano, , Italy
Naples, , Italy
Palermo, , Italy
Pisa, , Italy
Rome, , Italy
Siena, , Italy
Siena, , Italy
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported